Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.44 |
| ▸ | SCD | O00767 | 10/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224120 | 0.81 | SCD (0.45) | HCRTR1HCRTR2SCDCNR2 | |
| SCHEMBL3223079 | 0.81 | SCD (0.48) | SCDSIGMAR1 | |
| SCHEMBL3223397 | 0.80 | NPY5R (0.50) | SCD | |
| SCHEMBL3222392 | 0.78 | SCD (0.49) | SCD | |
| SCHEMBL3220004 | 0.77 | NPY5R (0.46) | SCD | |
| SCHEMBL3221535 | 0.76 | SCD (0.66) | HCRTR1HCRTR2SCD | |
| SCHEMBL3226074 | 0.76 | SCD (0.44) | SCDADRA1DADRA1AADRA1BSIGMAR1 | |
| SCHEMBL3222654 | 0.75 | SCD (0.45) | SCDSIGMAR1 | |
| SCHEMBL3231100 | 0.74 | SCD (0.46) | SCD | |
| SCHEMBL3219618 | 0.74 | SCD (0.47) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | HCRTR1 1829/4885HCRTR2 1318/4885SCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.